Docoh
Loading...

103 results

Filter options loading...
Top filers
Top filing types
Recent filing years
DEF 14A
PCSA Processa Pharmaceuticals Inc
20 Sep 21
Definitive proxy
2:51pm
at the meeting. What constitutes a quorum? The presence at the meeting, physically or by proxy, of the holders of a majority of all the outstanding … FOR votes from the holders of a majority of the issued and outstanding shares of common stock as of the record date. Accordingly, abstentions and broker
PRE 14A
PCSA Processa Pharmaceuticals Inc
1 Sep 21
Preliminary proxy
4:46pm
will not be permitted at the meeting. What constitutes a quorum? The presence at the meeting, physically or by proxy, of the holders of a majority of all … receive FOR votes from the holders of a majority of the issued and outstanding shares of common stock as of the record date. Accordingly, abstentions
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
, the presence, in person or by proxy, of the holders of a majority of the voting power of shares of our capital stock then outstanding will constitute a quorum
10-Q
2021 Q2
PCSA Processa Pharmaceuticals Inc
12 Aug 21
Quarterly report
4:01pm
to $1,329,213 when compared to $374,878 for the same period in 2020. The majority of the increase was due to an increase of $422,132 for professional
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
of directors. At any meeting to elect directors by holders of our common stock, the presence, in person or by proxy, of the holders of a majority of the voting
8-K
EX-10.1
29s3sak
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
10-Q
81kai53 wzdax3bgkb8c
13 May 21
Quarterly report
4:30pm
DEF 14A
qic0cri1qkemyjs9a
22 Apr 21
Definitive proxy
2:00pm
424B3
57iogzyb9fn34kb
12 Apr 21
Prospectus supplement
1:44pm
10-K/A
jth 8aljzvkjormo
7 Apr 21
Annual report (amended)
4:23pm
S-3
imh617t39pnq1izwe
1 Apr 21
Shelf registration
8:00pm
10-K
y2ws lm82wol6n
24 Mar 21
Annual report
8:00pm
10-K
EX-4.6
mitf03 n49zlm4ao993u
24 Mar 21
Annual report
8:00pm
8-K
EX-10.1
amu2oo9n6 9e1gg1zmi
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-10.2
3k3g jt45zvftdoin
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
10-Q
agytebw7uc4
12 Nov 20
Quarterly report
4:01pm
424B4
8a8a 1u2yc5goqf
5 Oct 20
Prospectus supplement with pricing info
4:16pm
S-1/A
7jgx62xehp ox
30 Sep 20
IPO registration (amended)
4:06pm
S-1/A
nk4jelwfvs 5v8kk4tn
16 Sep 20
IPO registration (amended)
8:00pm
S-1/A
EX-2.1
craphl6m rzdkj
16 Sep 20
IPO registration (amended)
8:00pm